Top

Published in:

01-08-2021 | Magnetic Resonance Imaging | Hepatobiliary-Pancreas

Gadobenate dimeglumine–enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis

Authors: Chenxi Liu, Yan Sun, Yao Yang, Yuemin Feng, Xiaoyu Xie, Lingyu Qi, Keke Liu, Ximing Wang, Qiang Zhu, Xinya Zhao

Published in: European Radiology | Issue 8/2021

Abstract

Objectives

To determine the value of gadobenate dimeglumine (Gd-BOPTA)–enhanced biliary imaging from the hepatobiliary phase in predicting hepatic decompensation and insufficiency for patients with cirrhosis.

Methods

This single-center retrospective study included 270 patients who underwent Gd-BOPTA-enhanced magnetic resonance imaging. The relative enhancement ratios of the biliary system (REB) and liver parenchyma (REL) in patients with normal liver function without underlying chronic liver disease and three groups of patients with Child-Pugh A, Child-Pugh B, and Child-Pugh C disease were measured. After a mean follow-up of 38.5 ± 22.5 months, prognostic factors were evaluated using the Cox proportional hazards regression model. Receiver operating characteristic (ROC) curve analyses were performed to assess the capacity of the REB and REL to predict the development of hepatic decompensation and insufficiency.

Results

During the follow-up period, nine of 79 patients with Child-Pugh A disease developed hepatic decompensation. The REB was a significant predictive factor (hazard ratio (HR) = 0.40 (0.19–0.84); p = 0.016), but the REL showed no association with hepatic decompensation. Moreover, the areas under the ROC curves (AUCs) were 0.83 and 0.52 for the REB and REL, respectively. Thirty-eight of 207 patients with cirrhosis developed hepatic insufficiency. The REB was a significant predictive factor (HR = 0.24 (0.13–0.46); p < 0.0001), but the REL did not show statistically significant association with hepatic insufficiency. The AUCs were 0.82 and 0.57 for the REB and REL, respectively.

Conclusions

Gd-BOPTA-enhanced biliary imaging from the hepatobiliary phase was valuable in predicting hepatic decompensation and insufficiency for cirrhotic patients.

Key Points

• Gd-BOPTA-enhanced biliary imaging was a significant predictive factor for hepatic decompensation in patients with cirrhosis.

• Gd-BOPTA-enhanced biliary imaging was a significant predictive factor for hepatic insufficiency in patients with cirrhosis.

• Gd-BOPTA-enhanced biliary imaging showed superior predictive values for adverse clinical outcomes compared to liver parenchymal imaging at the hepatobiliary phase.

Available only for authorised users

D'Amico G, Morabito A, D'Amico M et al (2018) Clinical states of cirrhosis and competing risks. J Hepatol 68:563–576PubMedCrossRef

Tsochatzis EA, Bosch J, Burroughs AK (2014) Liver cirrhosis. Lancet 383:1749–1761PubMedCrossRef

Garcia-Tsao G, Friedman S, Iredale J, Pinzani M (2010) Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology 51:1445–1449PubMedCrossRef

Fleming KM, Aithal GP, Card TR, West J (2010) The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. Aliment Pharmacol Ther 32:1343–1350PubMedCrossRef

Yoon JH, Lee JM, Kim E, Okuaki T, Han JK (2017) Quantitative liver function analysis: volumetric T1 mapping with fast multisection B₁ inhomogeneity correction in hepatocyte-specific contrast-enhanced liver MR imaging. Radiology 282:408–417PubMedCrossRef

Manos MM, Leyden WA, Murphy RC, Terrault NA, Bell BP (2008) Limitations of conventionally derived chronic liver disease mortality rates: results of a comprehensive assessment. Hepatology 47:1150–1157PubMedCrossRef

Moon AM, Singal AG, Tapper EB (2020) Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol 18:2650–2666PubMedCrossRef

Singh S, Fujii LL, Murad MH et al (2013) Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and metaanalysis. Clin Gastroenterol Hepatol 11:1573–1584PubMedPubMedCentralCrossRef

Kim BK, Kim HS, Yoo EJ et al (2014) Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. Hepatology 60:1911–1919PubMedCrossRef

10.

Rosenberg WM, Voelker M, Thiel R et al (2004) Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127:1704–1713PubMedCrossRef

11.

Singh S, Muir AJ, Dieterich DT, Falck-Ytter YT (2017) American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases. Gastroenterology 152:1544–1577PubMedCrossRef

12.

Shen Y, Wu SD, Wu L et al (2019) The prognostic role of liver stiffness in patients with chronic liver disease: a systematic review and dose-response meta-analysis. Hepatol Int 13:560–572PubMedCrossRef

13.

Asrani SK, Talwalkar JA, Kamath PS et al (2014) Role of magnetic resonance elastography in compensated and decompensated liver disease. J Hepatol 60:934–939PubMedCrossRef

14.

Lee DH, Lee JM, Chang W et al (2018) Prognostic role of liver stiffness measurements using magnetic resonance elastography in patients with compensated chronic liver disease. Eur Radiol 28:3513–3521PubMedCrossRef

15.

Takuma Y, Morimoto Y, Takabatake H, Toshikuni N, Tomokuni J, Sahara A (2017) Measurement of spleen stiffness with acoustic radiation force impulse imaging predicts mortality and hepatic decompensation in patients with liver cirrhosis. Clin Gastroenterol Hepatol 15:1782–1790PubMedCrossRef

16.

Nascimbeni F, Lebray P, Fedchuk L et al (2015) Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases. Clin Gastroenterol Hepatol 13:763–771PubMedCrossRef

17.

Friedrich-Rust M, Poynard T, Castera L (2016) Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastroenterol Hepatol 13:402–411PubMedCrossRef

18.

Bonatti M, Valletta R, Zamboni GA, Lombardo F, Senoner M, Simioni M (2019) Ascites relative enhancement during hepatobiliary phase after Gd-BOPTA administration: a new promising tool for characterising abdominal free fluid of unknown origin. Eur Radiol 29:2830–2836PubMedCrossRef

19.

Bonnaventure P, Cusin F, Pastor CM (2019) Hepatocyte concentrations of imaging compounds associated with transporter inhibition: evidence in perfused rat livers. Drug Metab Dispos 47:412–418PubMedCrossRef

20.

Li XM, Chen Z, Xiao EH, Shang QL, Ma C (2017) Diagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitis. World J Gastroenterol 23:3133–3141PubMedPubMedCentralCrossRef

21.

Zhao X, Huang M, Zhu Q, Wang T, Liu Q (2015) The relationship between liver function and liver parenchymal contrast enhancement on Gd-BOPTA-enhanced MR imaging in the hepatocyte phase. Magn Reson Imaging 33:768–773PubMedCrossRef

22.

Kozaka K, Kobayashi S, Yoneda N et al (2019) Doughnut-like hyperintense nodules on hepatobiliary phase without arterial-phase hyperenhancement in cirrhotic liver: imaging and clinicopathological features. Eur Radiol 29:6489–6498PubMedCrossRef

23.

Lewis S, Vasudevan P, Chatterji M et al (2016) Comparison of gadoxetic acid to gadobenate dimeglumine for assessment of biliary anatomy of potential liver donors. Abdom Radiol (NY) 41:1300–1309CrossRef

24.

Bastati N, Wibmer A, Tamandl D et al (2016) Assessment of orthotopic liver transplant graft survival on Gadoxetic acid-enhanced magnetic resonance imaging using qualitative and quantitative parameters. Invest Radiol 51:728–734PubMedCrossRef

25.

Blanche P, Dartigues JF, Jacqmin-Gadda H (2013) Review and comparison of ROC curve estimators for a time-dependent outcome with marker-dependent censoring. Biom J 55:687–704PubMedCrossRef

26.

Bantis LE, Nakas CT, Reiser B (2014) Construction of confidence regions in the ROC space after the estimation of the optimal Youden index-based cut-off point. Biometrics 70:212–223PubMedCrossRef

27.

Mir FF, Tomaszewski RP, Shuboni-Mulligan DD et al (2019) Chimeric mouse model for MRI contrast agent evaluation. Magn Reson Med 82:387–394PubMedPubMedCentralCrossRef

28.

Kukuk GM, Schaefer SG, Fimmers R et al (2014) Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests. Eur Radiol 24:2482–2490PubMedCrossRef

29.

Noda Y, Goshima S, Kajita K et al (2016) Biliary tract enhancement in gadoxetic acid-enhanced MRI correlates with liver function biomarkers. Eur J Radiol 85:2001–2007PubMedCrossRef

30.

Okada M, Ishii K, Numata K et al (2012) Can the biliary enhancement of Gd-EOB-DTPA predict the degree of liver function? Hepatobiliary Pancreat Dis Int 11:307–313PubMedCrossRef

31.

Takao H, Akai H, Tajima T et al (2011) MR imaging of the biliary tract with Gd-EOB-DTPA: effect of liver function on signal intensity. Eur J Radiol 77:325–329PubMedCrossRef

32.

Wu J, Li H, Lin Y, Chen Z, Zhong Q, Gao H (2015) Value of gadoxetate biliary transit time in determining hepatocyte function. Abdom Imaging 40:95–101PubMedCrossRef

33.

Lin CH, Ho CM, Wu CH et al (2020) Minimally invasive surgery versus radiofrequency ablation for single subcapsular hepatocellular carcinoma ≤ 2 cm with compensated liver cirrhosis. Surg Endosc 34:5566–5573PubMedCrossRef

34.

Choi HSJ, Brouwer WP, Zanjir WMR et al (2020) Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B. Hepatology 71:539–548PubMedCrossRef

35.

Garcia-Tsao G, Lim JK (2009) Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 104:1802–1829PubMedCrossRef

36.

Radcke S, Dillon JF, Murray AL (2015) A systematic review of the prevalence of mildly abnormal liver function tests and associated health outcomes. Eur J Gastroenterol Hepatol 27:1–7PubMedCrossRef

37.

Sandrasegaran K, Cui E, Elkady R et al (2018) Can functional parameters from hepatobiliary phase of gadoxetate MRI predict clinical outcomes in patients with cirrhosis? Eur Radiol 28:4215–4224PubMedCrossRef

38.

Khouri Chalouhi C, Vernuccio F, Rini F et al (2019) Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine. Eur Radiol 29:3090–3099PubMedCrossRef

39.

Tanimoto A, Lee JM, Murakami T, Huppertz A, Kudo M, Grazioli L (2009) Consensus report of the 2nd international forum for liver MRI. Eur Radiol 19:S975–S989PubMedCrossRef

40.

Matoori S, Froehlich JM, Breitenstein S et al (2019) Serum albumin, total bilirubin, and patient age are independent confounders of hepatobiliary-phase gadoxetate parenchymal liver enhancement. Eur Radiol 29:5813–5822PubMedCrossRef

41.

Geisel D, Raabe P, Lüdemann L et al (2017) Gd-EOB-DTPA-enhanced MRI for monitoring future liver remnant function after portal vein embolization and extended hemihepatectomy: a prospective trial. Eur Radiol 27:3080–3087PubMedCrossRef

Title: Gadobenate dimeglumine–enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis
Authors: Chenxi Liu
Yan Sun
Yao Yang
Yuemin Feng
Xiaoyu Xie
Lingyu Qi
Keke Liu
Ximing Wang
Qiang Zhu
Xinya Zhao
Publication date: 01-08-2021
Publisher: Springer Berlin Heidelberg
Keywords: Magnetic Resonance Imaging
Magnetic Resonance Imaging
Liver Cirrhosis
Published in: European Radiology / Issue 8/2021
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-021-07702-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Gadobenate dimeglumine–enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Please log in to get access to this content

Other articles of this Issue 8/2021

A clinically practical radiomics-clinical combined model based on PET/CT data and nomogram predicts EGFR mutation in lung adenocarcinoma

Spatiotemporal habitats from multiparametric physiologic MRI distinguish tumor progression from treatment-related change in post-treatment glioblastoma

Introducing the Node Reporting and Data System 1.0 (Node-RADS): a concept for standardized assessment of lymph nodes in cancer

Calcium scoring using virtual non-contrast images from a dual-layer spectral detector CT: comparison to true non-contrast data and evaluation of proportionality factor in a large patient collective

Cumulative effective dose from recurrent CT examinations in Europe: proposal for clinical guidance based on an ESR EuroSafe Imaging survey

Preoperative breast magnetic resonance imaging in patients with ductal carcinoma in situ: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC)